Workflow
LIVTAC分子XZ1606
icon
Search documents
中国科研团队研发新型肝纤维化靶向干预策略
Huan Qiu Wang Zi Xun· 2025-06-23 14:12
Core Viewpoint - The research teams from the Kunming Institute of Zoology and Shanghai Institute of Materia Medica have developed a novel liver-targeted protein degradation agent (LIVTAC) that effectively controls early hepatic fibrosis and inhibits the progression of late-stage tumors [1][3][5]. Group 1: Research and Development - LIVTAC is designed to target the liver specifically by utilizing the asialoglycoprotein receptor (ASGPR), allowing for precise degradation of liver-specific target proteins and effectively killing liver cancer cells [3][5]. - The research has shown that LIVTAC can reverse hepatic fibrosis and enhance metabolic function in murine models, indicating its potential for clinical application [5][6]. Group 2: Clinical Implications - Hepatic fibrosis is a critical pathological stage in the progression of chronic liver diseases, leading to cirrhosis and liver cancer, and current treatment options are limited to controlling the underlying causes [1][5]. - The development of LIVTAC represents a promising new intervention strategy that could reduce the incidence of mid-to-late stage liver diseases and improve long-term survival rates for patients [1][5].